{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:54:33Z","timestamp":1772776473847,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12328-022-01644-2","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T18:02:50Z","timestamp":1652896970000},"page":"776-783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab\u2013bevacizumab treatment"],"prefix":"10.1007","volume":"15","author":[{"given":"Takashi","family":"Hoshino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Furusawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsushi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-7093","authenticated-orcid":false,"given":"Satoru","family":"Kakizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"1644_CR1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","volume":"68","author":"N Fujiwara","year":"2018","unstructured":"Fujiwara N, Friedman SL, Goossens N, et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68:526\u201349.","journal-title":"J Hepatol"},{"key":"1644_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European association for the study of the liver EASL","year":"2018","unstructured":"European association for the study of the liver EASL. Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"1644_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/ph14010036","volume":"14","author":"T Hatanaka","year":"2021","unstructured":"Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for hepatocellular carcinoma: a literature review. Pharmaceuticals. 2021;14:36.","journal-title":"Pharmaceuticals"},{"key":"1644_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"1644_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"1644_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10:181\u2013223.","journal-title":"Liver Cancer"},{"key":"1644_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10120-016-0633-1","volume":"20","author":"Y Sato","year":"2017","unstructured":"Sato Y, Ohnuma H, Nobuoka T, et al. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer. 2017;20:517\u201326.","journal-title":"Gastric Cancer"},{"key":"1644_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0278","volume":"3","author":"G Tomasello","year":"2017","unstructured":"Tomasello G, Petrelli F, Ghidini M, et al. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3: e170278.","journal-title":"JAMA Oncol"},{"key":"1644_CR9","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.21873\/anticanres.13703","volume":"39","author":"Y Morine","year":"2019","unstructured":"Morine Y, Ikemoto T, Iwahashi S, et al. Clinical impact of FOLFOXIRI aiming for conversion surgery in unresectable multiple colorectal liver metastasis. Anticancer Res. 2019;39:5089\u201396.","journal-title":"Anticancer Res"},{"key":"1644_CR10","first-page":"475","volume":"83","author":"M Kudo","year":"2021","unstructured":"Kudo M, Aoki T, Ueshima K, Nishida N. Upfront systemic therapy with subsequent curative conversion for intermediate-stage hepatocellular carcinoma: atezolizumab + bevacizumab curative conversion (ABC Conversion) therapy. KanTanSui. 2021;83:475\u2013783.","journal-title":"KanTanSui"},{"key":"1644_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1159\/000519749","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M. A Novel treatment strategy for patients with intermediate-stage HCC who are not suitable for TACE: upfront systemic therapy followed by curative conversion. Liver Cancer. 2021;10:539\u201344.","journal-title":"Liver Cancer"},{"key":"1644_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"1644_CR13","doi-asserted-by":"publisher","first-page":"7663","DOI":"10.1245\/s10434-021-09974-0","volume":"28","author":"J Shindoh","year":"2021","unstructured":"Shindoh J, Kawamura Y, Kobayashi Y, et al. Prognostic impact of surgical intervention after lenvatinib treatment for advanced hepatocellular carcinoma. Ann Surg Oncol. 2021;28:7663\u201372.","journal-title":"Ann Surg Oncol"},{"key":"1644_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40164-021-00237-y","volume":"10","author":"Y Wang","year":"2021","unstructured":"Wang Y, Lu LC, Guan Y, et al. Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance. Exp Hematol Oncol. 2021;10:45.","journal-title":"Exp Hematol Oncol"},{"key":"1644_CR15","doi-asserted-by":"publisher","first-page":"82473","DOI":"10.18632\/oncotarget.12666","volume":"7","author":"H Zhang","year":"2016","unstructured":"Zhang H, Huang Z, Zou X, et al. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2016;7:82473\u201381.","journal-title":"Oncotarget"},{"key":"1644_CR16","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1245\/s10434-009-0447-z","volume":"16","author":"B Aussilhou","year":"2009","unstructured":"Aussilhou B, Dokmak S, Faivre S, et al. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol. 2009;16:1553\u20139.","journal-title":"Ann Surg Oncol"},{"key":"1644_CR17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","volume":"62","author":"JF Lu","year":"2008","unstructured":"Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharm. 2008;62:779\u201386.","journal-title":"Cancer Chemother Pharm"},{"key":"1644_CR18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/cpt.587","volume":"102","author":"M Stroh","year":"2017","unstructured":"Stroh M, Winter H, Marchand M, et al. Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin Pharm Ther. 2017;102:305\u201312.","journal-title":"Clin Pharm Ther"},{"key":"1644_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13748","author":"T Hatanaka","year":"2022","unstructured":"Hatanaka T, Hiraoka A, Tada T, et al. Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a landmark analysis. Hepatol Res. 2022. https:\/\/doi.org\/10.1111\/hepr.13748.","journal-title":"Hepatol Res"},{"key":"1644_CR20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"MS Lee","year":"2020","unstructured":"Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21:808\u201320.","journal-title":"Lancet Oncol"},{"key":"1644_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.1135","author":"J Arita","year":"2022","unstructured":"Arita J, Ichida A, Nagata R, et al. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors. J Hepatobiliary Pancreat Sci. 2022. https:\/\/doi.org\/10.1002\/jhbp.1135.","journal-title":"J Hepatobiliary Pancreat Sci"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01644-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-022-01644-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01644-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T13:57:14Z","timestamp":1659016634000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-022-01644-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1644"],"URL":"https:\/\/doi.org\/10.1007\/s12328-022-01644-2","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"31 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest in association with the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"The written informed consent was obtained from patients for this case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}